Osaka, Japan, February 15, 2017 and Raleigh, N.C., February 15, 2017 – PRA Health Sciences, Inc. （NASDAQ: PRAH,“PRA”） and Takeda Pharmaceutical Company Limited （TSE: 4502, “Takeda”） [...]
See the latest interactions from our social media
Researchers may have identified biological markers to distinguish different kinds of depression.… https://t.co/yZPtEopDmB
Last week, PRA Raleigh employees collected 589 pounds of food for the Urban Ministries Wake County Food Drive. #PRACares
Read the latest updates from our PR department
RALEIGH, N.C., Feb. 02, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its fourth quarter and year end 2016 results and issue 2017 guidance after the market closes on Wednesday, [...]
RALEIGH, N.C., Nov. 10, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced that one of its stockholders, consisting of an affiliate of, or a fund sponsored [...]
Explore the latest resources uploaded to our media library
Brought to you by PRA Health Sciences. A Bi-Weekly Industry Watch Newsletter
PRA recently performed a feasibility study to identify investigators who see patients with a rare neuromuscular autoimmune disease and who have the capability to perform a Phase II clinical trial.
PRA Health Sciences provides our clients with innovative solutions for CNS (neurology, psychiatry, and pain) drug development. Our work spans from early phase development to NDA and MAA submissions...
A large pharmaceutical client selected PRA to conduct 2 Phase III epilepsy studies in India, Eastern and Western Europe, and Australia. PRA’s project teams surpassed recruitment goals and achieved timely site activations despite administrative delays and tough competition for volunteers.